期刊
CURRENT CLINICAL PHARMACOLOGY
卷 5, 期 3, 页码 166-177出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157488410791498716
关键词
Targeted therapy; breast cancer; lung cancer; colorectal cancer; resistance; therapy individualization
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据